Today: 9 April 2026
Subscribe
Browse Category

NYSE:NVO 5 February 2026 - 12 March 2026

Hims & Hers Health Stock Price Jumps Again as Novo Nordisk Truce Sparks Wall Street Upgrades

Hims & Hers Health Stock Price Jumps Again as Novo Nordisk Truce Sparks Wall Street Upgrades

Hims & Hers Health shares climbed 5.1% to $27.19 in premarket trading Thursday, after closing up 10.3% Wednesday. The rally follows a deal with Novo Nordisk that ends a patent dispute and will return FDA-approved Wegovy and Ozempic to Hims’ platform later this month. Analysts raised targets but warned branded drugs may bring lower margins. Hims also disclosed an SEC probe and a Justice Department referral.
12 March 2026
···
Hims & Hers Stock Price Surges Nearly 50% in Two Days After Novo Deal, Analyst Upgrades

Hims & Hers Stock Price Surges Nearly 50% in Two Days After Novo Deal, Analyst Upgrades

Hims & Hers Health shares jumped 5.9% to $23.47 Tuesday after announcing a distribution deal with Novo Nordisk, extending a two-day gain to 49%. Novo withdrew its lawsuit against Hims as part of the pact, which will bring Ozempic and Wegovy to Hims’ platform and phase out most compounded GLP-1 drugs. Analysts raised price targets but warned branded drugs could lower margins. Regulatory risks remain.
11 March 2026
··
AbbVie Obesity Drug ABBV-295 Hits Up to 9.8% Weight Loss in Early Trial

AbbVie Obesity Drug ABBV-295 Hits Up to 9.8% Weight Loss in Early Trial

AbbVie said its experimental obesity drug ABBV-295 led to up to 9.79% weight loss in adults over 12 weeks in a 76-patient phase 1 trial, with no serious adverse events reported. Weekly and less-frequent dosing schedules showed similar results, while placebo groups saw little change. The study population was mostly male with a mean BMI under 30. ABBV-295 is not approved and remains in early-stage testing.
10 March 2026
····
Eli Lilly stock drops 2% as traders eye China approval and a late-day CFO readout

Eli Lilly stock drops 2% as traders eye China approval and a late-day CFO readout

Eli Lilly shares fell 2.3% to $1,028.07 Monday as health stocks lagged, despite the S&P 500 edging higher. Innovent Biologics won Chinese approval for Jaypirca, a Lilly-partnered cancer drug, after late-stage trial results. Investors remain focused on Lilly’s obesity drug pipeline and upcoming FDA decisions, with orforglipron inventory reaching $1.5 billion ahead of a possible U.S. launch.
2 March 2026
····
Hims & Hers stock steadies in premarket as Citi cuts target, SEC probe keeps GLP-1 risks in play

Hims & Hers stock steadies in premarket as Citi cuts target, SEC probe keeps GLP-1 risks in play

Hims & Hers Health shares rose 0.3% premarket after a 2.3% gain Wednesday, closing at $15.82. The company disclosed in its annual report that it faces an SEC investigation, a Justice Department referral, and a patent lawsuit from Novo Nordisk over compounded semaglutide products. BTIG downgraded the stock, citing regulatory risks and weak guidance. Citi cut its price target to $13.25 and maintained a “sell” rating.
26 February 2026
···
Eli Lilly stock price slips as Zepbound KwikPen FDA nod and Novo trial data keep LLY in focus

Eli Lilly stock price slips as Zepbound KwikPen FDA nod and Novo trial data keep LLY in focus

Eli Lilly shares fell 1.28% to $1,028.83 Wednesday after the FDA cleared a four-dose Zepbound KwikPen for obesity treatment. Novo Nordisk’s CagriSema showed less weight loss than Lilly’s tirzepatide in a head-to-head trial. Analysts called the gap significant for investors. Lilly said the new KwikPen will cost $299 per month at the 2.5 mg dose.
26 February 2026
···
Novo Nordisk stock slips again as CagriSema miss drives forecast cuts and puts next catalysts in focus

Novo Nordisk stock slips again as CagriSema miss drives forecast cuts and puts next catalysts in focus

Novo Nordisk shares fell 2.5% to 245.1 Danish crowns Tuesday after its CagriSema obesity drug failed to match Eli Lilly’s tirzepatide in a Phase 3 trial. Barclays cut its peak sales forecast for CagriSema to $2 billion from $12 billion. Novo also reported mid-stage China trial results for its “triple G” obesity drug UBT251, showing up to 19.7% weight loss after 24 weeks.
24 February 2026
··
Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod

Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod

Eli Lilly shares climbed nearly 5% late Monday after Novo Nordisk reported its obesity drug CagriSema underperformed Lilly’s Zepbound in a head-to-head trial. Novo’s U.S.-listed shares dropped over 16%. CagriSema showed 23% weight loss after 84 weeks, compared to 25.5% for Zepbound. The trial failed to prove CagriSema was not worse than tirzepatide on weight loss.
23 February 2026
····
Hims & Hers stock price slides again as Novo Nordisk lawsuit tightens the screws on Wegovy copies

Hims & Hers stock price slides again as Novo Nordisk lawsuit tightens the screws on Wegovy copies

Hims & Hers Health shares fell 5.6% to $18.25 Tuesday after Novo Nordisk filed a U.S. patent lawsuit seeking to block sales of compounded versions of its Wegovy weight-loss drug. The FDA has said semaglutide is no longer in shortage, tightening rules on compounding. Hims pulled its $49 compounded semaglutide pill days after launch. Investors await Hims’ earnings on Feb. 23.
10 February 2026
···
Hims & Hers stock drops again premarket as $49 weight-loss pill reversal fuels legal, FDA scrutiny

Hims & Hers stock drops again premarket as $49 weight-loss pill reversal fuels legal, FDA scrutiny

Hims & Hers Health shares dropped 4.2% to $18.52 premarket Tuesday after plunging 16% Monday. The company halted its compounded semaglutide pill following warnings from U.S. regulators and a new patent lawsuit by Novo Nordisk. The FDA signaled plans to restrict non-approved GLP-1 drugs and may take legal action. The Department of Health and Human Services referred Hims to the Justice Department.
10 February 2026
···
Hims & Hers stock sinks after $49 Wegovy copycat U-turn and Novo Nordisk lawsuit

Hims & Hers stock sinks after $49 Wegovy copycat U-turn and Novo Nordisk lawsuit

Hims & Hers Health shares plunged 16% in after-hours trading Monday after the company pulled its $49 compounded semaglutide pill amid a patent lawsuit from Novo Nordisk. The stock touched $16.44 before recovering some losses. Novo seeks a court order to stop sales of unapproved compounded drugs. Leerink Partners cut its price target on Hims, citing uncertainty over future sales of compounded semaglutide.
10 February 2026
···
Eli Lilly stock: what to watch Monday after FDA pressure forces Hims to pull a weight-loss pill

Eli Lilly stock: what to watch Monday after FDA pressure forces Hims to pull a weight-loss pill

Eli Lilly shares rose 3.7% to $1,058.18 Friday after Hims & Hers said it would halt sales of a compounded weight-loss pill following an FDA warning. U.S. regulators said they will crack down on mass-marketed, non-approved GLP-1 drugs. The FDA threatened legal action against violators and referred Hims to the Justice Department. Investors are watching for enforcement impact on obesity-drug pricing.
8 February 2026
···
Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

Novo Nordisk Class B shares closed up 5.3% at 295.50 Danish crowns in Copenhagen after Hims & Hers said it would stop offering a compounded pill version of Wegovy following U.S. regulatory warnings. The move came after Novo called the Hims product “illegal mass compounding” and threatened legal action. Shares had fallen nearly 8% Thursday after Hims launched the pill. Trading resumes Monday.
7 February 2026
··
Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

Eli Lilly shares rose 3.7% to $1,058.18 Friday after the FDA said it would act against telehealth firm Hims & Hers for marketing a $49 compounded weight-loss pill. The move followed a sharp selloff Thursday when Hims announced plans to sell a version of Novo Nordisk’s Wegovy. Investors remain uncertain how aggressively regulators will police copycat drugs and pricing in the obesity drug market.
7 February 2026
····
Eli Lilly stock rebounds after FDA flags copycat weight-loss drugs; what’s next for LLY

Eli Lilly stock rebounds after FDA flags copycat weight-loss drugs; what’s next for LLY

Eli Lilly shares rose 3% Friday after the FDA chief warned of a crackdown on non-approved copycat weight-loss drugs. The rebound followed an 8% drop Thursday, triggered by news of a $49 compounded rival to Novo Nordisk’s Wegovy. Investors are watching Lilly’s 2026 outlook and the FDA’s April decision on its oral obesity drug. Fourth-quarter revenue jumped 43% to $19.3 billion, led by strong sales of Mounjaro and Zepbound.
6 February 2026
····
Hims & Hers (HIMS) stock slides premarket as FDA targets “copycat drugs” over $49 Wegovy pill

Hims & Hers (HIMS) stock slides premarket as FDA targets “copycat drugs” over $49 Wegovy pill

Hims & Hers Health shares fell 3.8% to $23.48 in premarket trading Friday after FDA Commissioner Marty Makary warned of a crackdown on “illegal copycat drugs.” The drop followed Hims’ launch of a $49 compounded version of Novo Nordisk’s Wegovy pill. Novo Nordisk said it would pursue legal and regulatory action, calling Hims’ move “illegal mass compounding.” Investors are watching for FDA enforcement and lawsuits ahead of Hims’ Feb. 23 report.
6 February 2026
····
1 2 3 … 7

Stock Market Today

  • Microsoft (MSFT) Stock Undervalued by 17% After Recent Pullback, Says DCF Analysis
    April 9, 2026, 12:05 PM EDT. Microsoft shares declined 8.6% in the last 30 days and are down 20.9% year to date, closing at $374.33. Despite the pullback, a Discounted Cash Flow (DCF) analysis values the stock at approximately $452.80, indicating it trades at a 17.3% discount. The DCF model projects free cash flow rising from $93.7 billion to $164.8 billion by 2030, discounting future cash flows to present value. This suggests Microsoft may be undervalued compared to intrinsic worth. The company's valuation score is solid at 5 out of 6 according to Simply Wall St, amid continued focus on its technology sector dominance. Investors are advised to consider multiple valuation approaches to reassess Microsoft's attractiveness after recent price declines.

Latest article

Palantir Stock Drops as Michael Burry Says Anthropic Is ‘Eating Its Lunch’

Palantir Stock Drops as Michael Burry Says Anthropic Is ‘Eating Its Lunch’

9 April 2026
Palantir Technologies dropped about 7% Thursday after Michael Burry said Anthropic was overtaking it in enterprise AI, putting Palantir on track to lose $34 billion in market value. Anthropic reported its annualized revenue run rate had surged past $30 billion and launched new AI tools for businesses. Nearly one in four businesses on Ramp now pays for Anthropic, according to Ramp data. Palantir’s stock still trades at 395 times earnings.
Salesforce Stock Hits Fresh 52-Week Low Despite AI Growth and $50 Billion Buyback

Salesforce Stock Hits Fresh 52-Week Low Despite AI Growth and $50 Billion Buyback

9 April 2026
Salesforce shares hit a new 52-week low Thursday, dropping 3.7% to $169.76 despite reporting 12% revenue growth and strong demand for its AI products. The broader software sector continued to slide, with the S&P 500 software and services index down about $1 trillion since January. Salesforce raised its buyback authorization to $50 billion and increased its dividend to 44 cents a share.
ServiceNow Stock Hits Fresh 52-Week Low as Analysts Cut Targets Ahead of Earnings

ServiceNow Stock Hits Fresh 52-Week Low as Analysts Cut Targets Ahead of Earnings

9 April 2026
ServiceNow shares dropped 5.1% to $92.45 by 10:20 a.m. EDT Thursday, hitting a new 52-week low after analysts at Stifel, BTIG, and Goldman Sachs cut price targets citing weak federal spending and limited 2026 growth. The company announced it will integrate AI, data, security, and governance into all products ahead of first-quarter results due April 22.
SoFi Technologies Stock Slips as Wall Street Cuts Targets Ahead of Q1 Earnings

SoFi Technologies Stock Slips as Wall Street Cuts Targets Ahead of Q1 Earnings

9 April 2026
SoFi Technologies shares fell 1.9% to $16.18 Thursday after KBW and Wells Fargo cut price targets ahead of first-quarter results due April 29. The moves follow Muddy Waters’ short position and claims of accounting issues, which SoFi denies. Affirm and LendingClub also traded lower. Barclays and other banks have trimmed targets as concerns mount over credit quality and sector valuations.
Tesla revives cheaper EV bet with compact SUV plan in China after sales strain

Tesla revives cheaper EV bet with compact SUV plan in China after sales strain

9 April 2026
Tesla is developing a smaller, cheaper electric SUV to be built first in Shanghai, sources said. The new model would cost less than the Model 3 and be smaller than the Model Y. Tesla produced 408,386 vehicles but delivered only 358,023 in Q1, as U.S. demand weakened and competition increased. Shares fell 0.8% Thursday.
Go toTop